Canadian Institutes of Health Research Team in Aboriginal Antidiabetic Medicines, Department of Pharmacology, Université de Montréal, Montreal, QC, Canada.
J Ethnopharmacol. 2012 Jun 14;141(3):1012-20. doi: 10.1016/j.jep.2012.03.046. Epub 2012 Apr 4.
: In previous in vitro bioassay studies, Populus balsamifera L. (Salicaceae), a medicinal plant ethnobotanically identified from the traditional pharmacopoeia of the Cree of Eeyou Istchee (Eastern James Bay area of Canada), exhibited a strong anti-obesity potential by potently inhibiting adipogenesis in 3T3-L1 adipocytes. The aim of the study is to evaluate the effectiveness of this plant extract in mitigating the development of obesity and the metabolic syndrome in diet-induced obese (DIO) C57BL/6 mice.
Mice were subjected for eight weeks to a standard diet (CHOW), a high fat diet (HFD; DIO group), or HFD to which Populus balsamifera was incorporated at 125 and 250 mg/kg.
The results showed that Populus balsamifera decreased in a dose-dependent manner the weight gain of whole body, retroperitoneal fat pad and liver as compared to DIO controls and reduced the severity of hepatic macrovesicular steatosis and triglyceride accumulation. This plant extract also decreased glycemia in the second half of the feeding period and improved insulin sensitivity by diminishing insulin levels and the leptin/adiponectin ratio, as well as augmenting adiponectin levels. These effects were associated with slightly but significantly reduced food intake with 250 mg/kg Populus balsamifera as well as with an increase in energy expenditure (increase in skin temperature and increased expression of uncoupling protein-1; UCP-1). Data also suggest other mechanisms, such as inhibition of adipocyte differentiation, decrease of hepatic inflammatory state and potential increase in hepatic fatty acid oxidation.
Taken together, these results confirm the potential of Populus balsamifera as a culturally adapted therapeutic approach for the care and treatment of obesity and diabetes among the Cree.
在之前的体外生物测定研究中，从加拿大东詹姆斯湾地区克里族传统药物中鉴定出的药用植物香脂杨（柳科），通过强烈抑制 3T3-L1 脂肪细胞中的脂肪生成，表现出很强的抗肥胖潜力。本研究的目的是评估该植物提取物在减轻饮食诱导肥胖（DIO）C57BL/6 小鼠肥胖和代谢综合征发展中的有效性。
小鼠接受 8 周标准饮食（CHOW）、高脂肪饮食（HFD；DIO 组）或 HFD 喂养，同时添加 125 和 250mg/kg 的香脂杨提取物。
结果表明，与 DIO 对照组相比，香脂杨提取物以剂量依赖的方式降低了全身、腹膜后脂肪垫和肝脏的体重增加，并减轻了肝大泡性脂肪变性和甘油三酯积累的严重程度。这种植物提取物还降低了喂养期后半段的血糖水平，并通过降低胰岛素水平和瘦素/脂联素比值，以及增加脂联素水平，改善胰岛素敏感性。这些作用与 250mg/kg 香脂杨提取物稍微但显著降低食物摄入量以及增加能量消耗（皮肤温度升高和解偶联蛋白-1（UCP-1）表达增加）有关。数据还表明其他机制，如抑制脂肪细胞分化、降低肝炎症状态和潜在增加肝脂肪酸氧化。
综上所述，这些结果证实了香脂杨作为一种文化适应性治疗方法，用于治疗克里族肥胖和糖尿病的潜力。
